ID   M249 R4
AC   CVCL_EI93
SY   M249-AR4; M249AR4
DR   cancercelllines; CVCL_EI93
DR   Cosmic; 1545619
DR   Wikidata; Q54903563
RX   PubMed=21107323;
RX   PubMed=22194965;
RX   PubMed=25645078;
CC   Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; PLX4032).
CC   Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=22194965; PubMed=25645078).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22194965; PubMed=25645078).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=21107323; PubMed=22194965; PubMed=25645078).
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_D755 ! M249
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 26-09-16; Last updated: 05-10-23; Version: 11
//
RX   PubMed=21107323; DOI=10.1038/nature09626;
RA   Nazarian R., Shi H.-B., Wang Q., Kong X.-J., Koya R.C., Lee H.,
RA   Chen Z.-G., Lee M.-K., Attar N., Sazegar H., Chodon T., Nelson S.F.,
RA   McArthur G.A., Sosman J.A., Ribas A., Lo R.S.;
RT   "Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or
RT   N-RAS upregulation.";
RL   Nature 468:973-977(2010).
//
RX   PubMed=22194965; DOI=10.1371/journal.pone.0028973;
RA   Atefi M., von Euw E.M., Attar N., Ng C., Chu C., Guo D.-L., Nazarian R.,
RA   Chmielowski B., Glaspy J.A., Comin-Anduix B., Mischel P.S., Lo R.S.,
RA   Ribas A.;
RT   "Reversing melanoma cross-resistance to BRAF and MEK inhibitors by
RT   co-targeting the AKT/mTOR pathway.";
RL   PLoS ONE 6:E28973-E28973(2011).
//
RX   PubMed=25645078; DOI=10.1186/s12943-015-0293-5;
RA   Atefi M., Titz B., Avramis E., Ng C., Wong D.J.L., Lassen A.,
RA   Cerniglia M., Escuin-Ordinas H., Foulad D., Comin-Anduix B.,
RA   Graeber T.G., Ribas A.;
RT   "Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma.";
RL   Mol. Cancer 14:27.1-27.12(2015).
//